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LETTERS TO THE EDITOR
Podocin mutations in
sporadic focal-segmental
glomerulosclerosis occurring
in adulthood
To the Editor: Podocin is a key component of the podo-
cyte slit diaphragm. Mutations of podocin cause recessive
steroid-resistant nephrotic syndrome that evolves to renal
failure in early childhood [1]. They have also been found
in children with sporadic nephrotic syndrome [2] and vari-
able outcome including patients with steroid and cyclospo-
rine sensitivity [3].
Herein, we present the results of podocin mutation
screening in 64 adults with steroid resistant nephrotic syn-
drome, showing the presence of heterozygous mutation
in three. Two were new mutations [i.e., S211T and H325Y
(Fig. 1)]; the remaining one (i.e., P20L) was frequently
Fig. 1. Electropherogram of two new podocin mutations. Conservationobserved in children. New mutations determine an amino of the mutated amino acids through species is also reported.
acid change in exon 5 (nucleotide 631 T-A) and exon
8 (nucleotide 973 C-T), respectively, being the wild-type
conserved in mouse and rat (Fig. 1). Clinical features were
REFERENCEScomparable in the three patients. All were unresponsive
1. Boute N, Gribouval O, Roselli S, et al: NPHS2, encoding theto drugs (steroids and cyclosporine) and progressed to
glomerular protein podocin, is mutated in autosomal recessive steroid-end-stage renal failure. Age at onset of proteinuria varied resistant nephrotic syndrome. Nat Genet 24:349–354, 2000
from 21 and 34 years in the case of H325Y and S211T, 2. Caridi G, Bertelli R, Carrea A, et al: Prevalence, genetics, and
clinical features of patients carrying podocin mutations in steroid-respectively, and to 60 years of the patient with the P20L.
resistant nonfamilial focal segmental glomerulosclerosis. J Am SocFocal-segmental glomerulosclerosis (FSGS) was present Nephrol 12:2742–2746, 2001
3. Caridi G, Bertelli R, Di Duca M, et al: Broadening the spectrumin the two patients for whom a renal biopsy was available
of diseases related to podocin mutations. J Am Soc Nephrol, 2003(H325Y and S211T). The same two patients received a
renal transplant and recurrence occurred in one patient.
These data describe podocin mutations in adults with
FSGS and confirm the association with a wide range of Mycophenolate mofetil
clinical characteristics. Molecular analysis of podocin
should be extended to adults with FSGS since may modify prevents development of
the therapeutic approach in these patients.
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To the Editor: Mycophenolate mofetil (MMF) is a po-Correspondence to Gian Marco Ghiggeri, M.D., Laboratory on Patho-
tent immunosuppressant that has been successfully usedphysiology of Uremia, G. Gaslini Institute, Largo G. Gaslini 5, I-16147,
Genoa, Italy. in clinical organ transplantation [1]. Besides preventing
E-mail: labnefro@ospedale-gaslini.ge.it acute and chronic rejection of the grafted organs postoper-
atively, MMF has a potential to prevent progression of
nephropathy [2, 3]. Utimura et al [2] reported that admin-
istration of 10 mg/kg/day of MMF to Munich-Wistar rats 2003 by the International Society of Nephrology
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with diabetes induced by streptozotocin after uninephrec- condition, grew at the same rate as untreated controls,
and developed no anemia (hematocrit  42  1% intomy prevented albuminuria for a long period.
We also verified whether MMF prevents development diabetic treated vs. 44  1% in untreated at 8 months of
observation, P  0.1). We avoided higher doses, which,of anti-glomerular basement membrane (GBM) antibody-
induced glomerulonephritis. Experimental nephritis in in pilot studies, were systematically associated with anemia,
stunted growth, and poor general condition. MMF hasWKY/NCrj (MHC haplotype; RT1l) rats was induced by
an intraperitoneal injection of anti-GBM antibody (SR2). been associated with reversible anemia in transplant pa-
tients, suggesting that it may indeed depress the ery-Then, the animals were given 20 mg/kg/day of oral MMF
(treated group) or normal saline (control group) for 2 throid series [1]. We believe this is dose-dependent, and
that MMF doses should be carefully titrated if this andweeks. The results showed MMF significantly prevented
urinary protein excretion (treated group vs. control other untoward effects are to be avoided. We are un-
aware of data on variable susceptibility among rat strains,group, 9.4  4.3/creatinine vs. 21.7  4.3/creatinine).
However, daily administration of MMF significantly re- although this is certainly possible.
duced the hematocrit level (24.0 0.8% vs. 41.7 1.5%)
Ricardo Utimura, Clarice K. Fujihara,and suppressed body weight gain (13.4 6.8% vs. 20.7
Ana Lu´cia Mattar, Denise MacMalheiros,7.0%). We paid much attention to MMF dosage for dif- Irene L Noronha, and Roberto Zatz
ferent rat strains. Few adverse effects occurred when Sa˜o Paulo, Brazil
we administered 20 mg/kg/day of MMF to Lewis rats
Correspondence to Ricardo Utimura, M.D., Renal Division, Depart-(haplotype; RT1l) in another experimental model. It was
ment of Clinical Medicine, University of Sa˜o Paulo, Sa˜o Paulo, SP, Brazil.
also reported that even when 80 mg/kg/day was orally E-mail: rzatz@usp.br; ricauti@usp.br
administered to BN rats (RT1n), no adverse effects oc-
curred [3]. Because MMF is a critical dose drug and REFERENCES
markedly affected by sensibility, there may be differ-
1. Arbeiter K, Greenbaum L, Balzar E, et al: Reproducible erythroidences in doses among experimental animals, such as 10 aplasia caused by mycophenolate mofetil. Pediatr Nephrol 14:195–
mg/kg/day [2] and 80 mg/kg/day [3]. 197, 200
We congratulate Utimura et al [2] for their new ap-
proach to diabetic nephropathy, but wish to know if any
adverse effects such as anemia and clinical symptoms Myocardial function in
occurred.
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E-mail: eijikoba@jichi.ac.jp electrocardiogram in Gitelman’s syndrome and concluded
with the suggestion of increased risk for these patients of
REFERENCES developing dangerous ventricular arrhytmias.
Although on a general basis this possibility cannot be1. Shaw LM, Korecka M, DeNofrio D, Brayman KL: Pharmaco-
kinetic, pharmacodynamic, and outcome investigations as the basis ruled out, we believe that prolonged QT interval does
for mycophenolic acid therapeutic drug monitoring in renal and not represent a peculiar finding of the disease commonly
heart transplant patients. Clin Biochem 34:17–22, 2001
caused by hypokalemia and hypomagnesemia, per se.2. Utimura R, Fujihara CK, Mattar AL, et al: Mycophenolate mofetil
prevents the development of glomerular injury in experimental dia- Moreover, the level of corrected prolonged QT interval
betes. Kidney Int 63:209–216, 2003 that identifies, in association with syncope, a high-risk
3. Nieto E, Escudero E, Navarro E, et al: Effects of mycophenolate
patient for development of ventricular arrhythmias ismofetil in mercury-induced autoimmune nephritis. J Am Soc Neph-
longer than 500 ms, which was found in only 1 out of 27rol 13:937–945, 2002
patients included in the study. Finally, to the best of our
Reply from the Authors knowledge, there is no report of sudden death in patients
with Bartter’s or Gitelman’s syndrome. In our cohort ofWe wish to thank Dr. Takeda and his colleagues for
their remarks. In the study in question, and in prior Bartter’s patients, whose genetic characterization later
allowed the diagnosis of affected by Bartter’s or Gitel-studies of the 5/6 renal ablation and the chronic nitric
oxide inhibition models, we always administered myco- man’s syndrome, however, we reported specific abnor-
malities of cardiac function, independent of hypoka-phenolate mofetil (MMF) at 10 mg/kg/day. At this dose,
diabetic rats ate normally, remained in good “clinical” lemia, characterized by the inability to adequately recruit
